Opsidio, LLC, a US-based clinical stage biotechnology company, announced on Wednesday that it has dosed its first subject in the Phase 2a clinical trial of OpSCF, the company's pioneering monoclonal antibody against stem cell factor, in subjects suffering from moderate to severe atopic dermatitis.
The company is collaborating with AbbVie for the development of OpSCF.
The study, a randomised, double-blind, placebo-controlled, Phase 2a study, is to assess the efficacy and safety of OpSCF in the treatment of adults with moderate to severe atopic dermatitis. The primary endpoint is the percent change in the Eczema Area and Severity Index (EASI) score from baseline, at week 16, while the secondary endpoint comprises safety and tolerability and improvement in pruritus, body surface area, and quality of life.
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
PRISM BioLab partners with Talus Bioscience to address TF and PPI targets
Thryv Therapeutics reports positive Phase 1 results for THRV-1268